A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

750

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 16, 2026

Study Completion Date

December 14, 2026

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSVPreF3 OA vaccine

1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

BIOLOGICAL

Placebo

1 dose of saline solution administered intramuscularly in the deltoid region of the non-dominant arm.